Skip to main content
A
AKTS
(NASDAQ)
Aktis Oncology, Inc.
$18.50-- (--)
Loading... - Market loading

Aktis Oncology (AKTS) Income Statement

Revenue, expenses, profit margins, and earnings with annual and quarterly data.

Aktis Oncology Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Aktis Oncology, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period EndingDec 2025Dec 2024Dec 2023Dec 2022
Revenue & Gross Profit
Revenue6.501.490.000.00
Cost of Revenue0.0040.950.000.00
Gross Profit6.501.490.000.00
Operating Expenses
Research & Development67.4540.9525.9214.30
Selling, General & Administrative12.6011.317.685.11
Operating Expenses81.1853.5434.7919.76
Operating Income-74.68-52.05-34.79-19.76
Other Income/Expense
Interest Income11.018.105.381.65
Interest Expense0.000.000.000.00
Other Income/Expense10.95-0.030.781.84
Income
Income Before Tax-63.73-43.98-28.64-17.93
Income Tax Expense0.000.000.000.00
Net Income-63.73-43.98-28.64-17.93
Net Income - Continuous Operations-63.73-43.98-28.64-17.93
Net Income - Discontinued Operations0.000.000.000.00
EBITDA-72.36-50.48-33.60-19.32
EBIT-74.68-52.05-34.79-19.76
Depreciation & Amortization2.331.281.200.45
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00
Diluted EPS-1.00-1.00-1.00-1.00
Basic Shares Outstanding52.5234.8634.8634.86
Diluted Shares Outstanding52.5234.8634.8634.86

These financial metrics are calculated using income statement data. Learn how each metric works and screen stocks by them.